Hepatobiology and Toxicology COBRE

肝脏生物学和毒理学 COBRE

基本信息

批准号：
10026250
负责人：
CRAIG J. MCCLAIN
金额：
$ 234万
依托单位：
UNIVERSITY OF LOUISVILLE
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-06-10 至 2026-03-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10026250
关键词：
Acute Liver Failure Address Adult Affect Alcoholic Liver Diseases American Area Basic Science Biomedical Research Centers of Research Excellence Child Cirrhosis Collaborations Communication Communities Complex Core Facility Data Analyses Development Diabetes Mellitus Discipline Drug Interactions Drug abuse Ensure Environment Enzymes FDA approved Fostering Funding Goals Grant Health Hepatitis A Hepatitis B Hepatitis C Home Homelessness Industrialization Industry Injury International Kentucky Laboratories Link Liver Liver Failure Liver diseases Mentors Metabolic syndrome Metabolism Molecular Target Morbidity - disease rate National Institute on Alcohol Abuse and Alcoholism Obesity Organ Overweight Pharmaceutical Preparations Pharmacotherapy Phase Phase I Clinical Trials Prevention Primary carcinoma of the liver cells Process Program Sustainability Publications Research Research Infrastructure Research Personnel Research Project Grants Resources Scientist Structure Technology Therapeutic Toxic Environmental Substances Toxicant exposure Toxicology Translational Research United States National Institutes of Health Universities University resources biobank career development clinical practice education research experience liver injury liver transplantation member multidisciplinary non-alcoholic fatty liver disease nonalcoholic steatohepatitis novel novel therapeutics nutrition personalized medicine prevent programs recruit success toxicant viral liver disease

项目摘要

The University of Louisville (UofL) Hepatobiology and Toxicology (H&T) COBRE is a unique thematic center focused on liver research. The UofL H&T COBRE concentrates on the mechanisms and therapeutic strategies for multiple forms of liver disease/injury, including: Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis—the most common liver disease in the US/worldwide, and is highly linked to the metabolic syndrome; Alcoholic Liver Disease—a common problem among those who drink; Environmental Toxicant Induced Liver Injury—an increasingly recognized problem, and Louisville has been a leader in this area; Hepatitis B and C—important causes of cirrhosis and hepatocellular carcinoma worldwide; Personalized Medicine—an increasingly important factor in medication efficacy, and most drugs are metabolized in the liver; and Drug-Induced Liver Injury—the most common reason drugs are removed from the market and an important cause of liver failure. This COBRE brings together experienced senior mentors/investigators and promising junior investigators to perform cross-cutting research on the unique topics of Hepatobiology and Toxicology. We address critical barriers in our understanding of the development/ progression of liver disease and we define targets for prevention/treatment that could transform clinical practice. Specific Aims of the Hepatobiology and Toxicology COBRE are to: 1. Expand and strengthen a thematically-focused program in Hepatobiology and Toxicology that helps build and sustain the overall research infrastructure at UofL. 2. Expand and strengthen the multidisciplinary program in research education, mentoring and career development in Hepatobiology and Toxicology, and systematically track and evaluate the progress. 3. Provide the necessary research resources and translational science/basic technologies to support state-of- the-art research in Hepatobiology and Toxicology and to ensure sustainability of the program. 4. Discover new mechanisms/molecular targets and effective means for preventing and/or treating liver diseases/toxicant exposures and communicate our findings to the public. In summary, Phase I strengthened UofL’s biomedical research infrastructure through the establishment of a thematic multidisciplinary center in hepatobiology and toxicology to enhance the ability of investigators to compete for independent funding. In Phase I, we met or exceeded our metrics, including 1) four of our investigators transitioning to independent research funding; 2) 91 mentee and 162 total publications; 3) new renovated laboratory space; 4) numerous presentations; 5) establishing new collaborations; and 6) >$75 million in total new grant funding by H&T members. This Phase II proposal builds on our Phase I success, extends and strengthens the scope of the program, and provides a roadmap for sustainability.

路易斯维尔大学（UOFL）肝病学和毒理学（H＆T）Cobre是一个独特的主题中心专注于肝脏研究。 UOFL H＆T COBRE集中在机制和治疗上。多种形式的肝病/损伤的策略，包括：非酒精性脂肪肝疾病/非酒精性脂肪性肝炎 - 美国/全球最常见的肝病，与代谢高度相关综合征；酒精性肝病 - 喝酒的人常见问题；环境有毒物质诱发肝损伤 - 一个越来越认可的问题，路易斯维尔一直是该领域的领导者。丙型肝炎和C-全球肝硬化和肝细胞癌的重要原因；个性化药物 - 药物效率越来越重要的因素，大多数药物在肝脏中被代谢；和药物引起的肝损伤 - 最常见的原因是从市场中删除药物的原因肝衰竭的重要原因。该鞋底汇集了经验丰富的高级导师/调查员和有前途的初级调查人员就肝脏生物学和毒理学。我们在理解肝病的发展/进展方面解决了关键的障碍我们定义了可以改变临床实践的预防/治疗目标。肝生物学和毒理学的具体目的是： 1。扩展和加强肝病学和毒理学领域的主题计划，有助于建立并维持UOFL的整体研究基础设施。 2。扩展和加强研究教育，心理和职业领域的多学科计划肝病学和毒理学的发展，并系统地跟踪和评估进度。 3。提供必要的研究资源和转化科学/基本技术，以支持最新肝病学和毒理学方面的艺术研究，并确保该计划的可持续性。 4。发现新的机制/分子靶标和预防和/或治疗肝脏的有效手段疾病/有毒物质暴露并向公众传达我们的发现。总而言之，第一阶段通过建立加强了UOFL的生物医学研究基础设施肝病学和毒理学的主题多学科中心，以增强研究人员的能力争夺独立资金。在第一阶段，我们达到或超过了指标，包括1）我们的四个调查人员过渡到独立研究资金； 2）91个Menee和162个出版物； 3）新翻新的实验室空间； 4）许多演讲； 5）建立新的合作；和6）> $ 75 H＆T成员的全新赠款资金总额为百万。该第二阶段提案建立在我们的第一阶段成功之上，扩展并实现了该计划的范围，并为可持续性提供了路线图。